Skip to main navigation Skip to search Skip to main content

Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium

  • on behalf of the International Transporter Consortium
  • Merck
  • University of Toronto
  • GlaxoSmithKline
  • Radboud University Nijmegen
  • Takeda Pharmaceutical Company
  • Genentech, Inc
  • University of Pittsburgh
  • University of North Carolina at Chapel Hill

Research output: Contribution to journalReview articlepeer-review

111 Scopus citations

Abstract

Drug transporters are critically important for the absorption, distribution, metabolism, and excretion (ADME) of many drugs and endogenous compounds. Therefore, disruption of these pathways by inhibition, induction, genetic polymorphisms, or disease can have profound effects on overall physiology, drug pharmacokinetics, drug efficacy, and toxicity. This white paper provides a review of changes in transporter function associated with acute and chronic disease states, describes regulatory pathways affecting transporter expression, and identifies opportunities to advance the field.

Original languageEnglish
Pages (from-to)900-915
Number of pages16
JournalClinical Pharmacology and Therapeutics
Volume104
Issue number5
DOIs
StatePublished - Nov 2018

Fingerprint

Dive into the research topics of 'Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium'. Together they form a unique fingerprint.

Cite this